Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: A prospective clinical study

Hypertension

Volumn 55, Issue 5, 2010, Pages 1137-1142

  Gaddam, Krishna ^a   Corros, Cecilia ^a   Pimenta, Eduardo ^a,g   Ahmed, Mustafa ^a   Denney, Thomas ^c,d   Aban, Inmaculada ^b   Inusah, Seidu ^b   Gupta, Himanshu ^a   Lloyd, Steven G ^a   Oparil, Suzanne ^a   Husain, Ahsan ^a,f   Dell'Italia, Louis J ^a,e   Calhoun, David A ^a  

^a Division of Cardiovascular Disease   (United States)

^b Biophysics and Bioengineering   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d AUBURN UNIVERSITY   (United States)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cardiac hypertrophy; Cardiac volume; Hyperaldosteronism; Resistant hypertension

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID RECEPTOR; RENIN; SPIRONOLACTONE; VASODILATOR AGENT;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; DRUG DOSE TITRATION; DRUG SUBSTITUTION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE OVERLOAD; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MALE; OUTCOME ASSESSMENT; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; REMISSION;

AGE OF ONSET; CARDIAC VOLUME; CREATININE; DIASTOLE; DIURETICS; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEART ATRIA; HEART RATE; HEART VENTRICLES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SODIUM; SPIRONOLACTONE; STROKE VOLUME; SYSTOLE;

EID: 77951499272     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.141531     Document Type: Article

References (41)

1. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33-41. (Pubitemid 38857245)
2. Fardella CE, Mosso L, Gómez-Sánchez C, Cortés P, Soto J, Gómez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyper-aldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000;85:1863-1867. (Pubitemid 32269290)
3. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens. 2000;14:311-315. (Pubitemid 30311512)
4. Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161-165. (Pubitemid 36944590)
5. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005;51:386-394.
6. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rissoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, for the PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293-2300. (Pubitemid 44873058)
7. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37:699-705.
8. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissman P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892-896. (Pubitemid 35434912)
9. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003;17:349-352. (Pubitemid 36625965)
10. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:2217-2226. (Pubitemid 39463817)
11. Umpierrez GE, Cantey P, Smiley D, Palacio A, Temponi D, Luster K, Chapman A. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care. 2007;30:1699-1703. (Pubitemid 47036339)
12. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039-1045. (Pubitemid 26140658)
13. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis. 1999;33:261-266. (Pubitemid 29072226)
14. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248. (Pubitemid 40523144)
15. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldoste-ronism after treatment. Arch Intern Med. 2008;68:80-85.
16. Schlaich MP, Schobel HP, Hilgers K, Schmieder RE. Impact of aldoste-rone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol. 2000;85:1199-1206. (Pubitemid 30232814)
17. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldoste-ronism. Hypertension. 2002;40:23-27. (Pubitemid 34755974)
18. Matsumura K, Fujii K, Oniki H, Oka M, Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens. 2006;19:13-18. (Pubitemid 43217027)
19. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90:5070-5076. (Pubitemid 41262256)
20. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893-901.
21. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spirono-lactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993;71:12A-16A.
22. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578-2583. (Pubitemid 24177174)
23. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 1995;269:E657-E662.
24. Law PH, Sun Y, Bhattacharya S, Chhokar VS, Weber KT. Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol. 2005;46:142-146. (Pubitemid 40905142)
25. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT. Hyperparathyroidism and calcium paradox of aldosteronism. Circulation. 2005;111:871-878.
26. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol. 2002;283: H1802-H1810. (Pubitemid 35217013)
27. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension aldosterone and persistent intra-vascular volume expansion. Arch Intern Med. 2008;168:1159-1164. (Pubitemid 351831398)
28. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008;51:339-344. (Pubitemid 351159948)
29. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463. (Pubitemid 41821197)
30. Lawson MA, Blackwell GG, Davis NG, Roney M, Dell'Italia LJ, Pohost GM. Accuracy of biplane long-axis left ventricular volume determined by cine magnetic resonance imaging in patients with regional and global dysfunction. Am J Cardiol. 1996;77:1098-1104. (Pubitemid 26183727)
31. Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen acitivator inhibitor-1 deficiency protects against aldoste-rone-induced glomerular injury. Kidney Int. 2006;69:1064-1072. (Pubitemid 43372182)
32. Makahova N, Hagaman J, Kim H-S, Smithies O. Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. Hypertension. 2008;51:134-140. (Pubitemid 350307115)
33. Fletcher EC, Bao G, Li R. Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension. 1999;34:309-314. (Pubitemid 29409233)
34. Fletcher EC, Orolinova N, Bader M. Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system. J Appl Physiol. 2002;92: 627-633. (Pubitemid 34671030)
35. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of non rheumatic atrial fibrillation: the Framingham Heart Study. Circulation. 1994;89:724-730. (Pubitemid 24056200)
36. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death: the Framingham Heart Study. Circulation. 1995;92:835-841.
37. Moller JE, Hillis GS, Oh JK, Seward JB, Reeder GS, Wright RS, Park SW, Bailey KR, Pellikka PA. Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation. 2003;107:2207-2212. (Pubitemid 36547214)
38. Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of calcium metabolism and of parathyroid function in primary aldoste-ronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens. 1995;8:884-893.
39. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004;109:2857-2861. (Pubitemid 38780298)
40. Wilson IM, Freis ED. Relationship between plasma and extracellular fluid volume depletion and the antihypertensive of chlorothiazide. Circulation. 1959;20:1028-1036.
41. Conway J, Lauwers P. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation. 1960;21:21-27.